RCM
IRD

Regency Capital Management’s Opus Genetics IRD Stock Holding History

Regency Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$309K Buy
68,000
+22,000
+48% +$76.1K 0.14% 57
2025
Q4 		$92.5K Buy
+46,000
New +$93.4K 0.04% 61
2021
Q4 		– Sell
-15,000
Closed -$60.1K – 174
2021
Q3 		$77K Hold
15,000
– – 0.05% 79
2021
Q2 		$79K Sell
15,000
-2,000
-12% -$9.93K 0.06% 76
2021
Q1 		$99K Buy
+17,000
New +$158K 0.1% 80

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Regency Capital Management's IRD Position: Q1 2026 in Review

Regency Capital Management increased its Opus Genetics (IRD) stake by 48% in Q1 2026, buying an estimated $76.1K and bringing the position to 68,000 shares worth $309K. The position accounts for 0.14% of the portfolio, ranked #57.

Regency Capital Management first reported a position in IRD in Q1 2021 and has held it in 5 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Regency Capital Management held 68,000 shares of Opus Genetics worth $309K as of Q1 2026.
  • Regency Capital Management bought 22,000 Opus Genetics shares in Q1 2026, an estimated $76.1K.
  • Opus Genetics made up 0.14% of Regency Capital Management's portfolio in Q1 2026, its #57 holding.
  • Regency Capital Management first reported a position in Opus Genetics in Q1 2021 and has held it in 5 quarters since.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Regency Capital Management's 13F filing for Q1 2026, filed 5 May 2026.